This is a phase II open label study on the use of Ibrutinib on the inhibition of food-induced
anaphylaxis in adults with food allergy. Ibrutinib (brand name Imbruvica) is currently FDA
approved for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL),
and Waldenstrom's macroglobulineia (WM). We propose to administer this approved drug to
adults with food allergy to inhibit food allergy responses.
Phase:
Phase 2
Details
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborator:
Feinberg School of Medicine, Northwestern University